Company: BDRX
Filing Date: 2025-05-08
Form Type: POS AM
Source: 0001214659-25-007201
Chunk: 121

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-05-08
Form: POS AM
Chunk 121
---
’s request.

Insofar as indemnification
for liabilities arising under the Securities Act of 1933, as amended, may be permitted to directors, officers or persons controlling us
pursuant to the foregoing provisions, we have been informed that in the opinion of the Securities and Exchange Commission such indemnification
is against public policy as expressed in the Securities Act and is, therefore, unenforceable.

| Item 7. | Recent Sales of Unregistered 
 Securities                   |

The following information is furnished with
regard to all securities issued by the registrant within the last three years that were not registered under the Securities Act of 1933,
as amended. Unless otherwise indicated below, the issuance of such shares was deemed exempt from registration requirements of the Securities
Act, of 1933, as amended, as such securities were offered and sold outside of the United States to persons who were neither citizens nor
residents of the United States, pursuant to Regulation S, or such sales were exempt from registration under Section 4(2) of Securities
Act of 1933, as amended and Rule 506 of Regulation D promulgated thereunder.

On February 15, 2023, we completed the closing of a private placement pursuant to which we sold to certain institutional investors (1) 3,250,000 Ordinary Shares represented by 325 Depositary Shares at $4,640.00 per Depositary Share, (2) 12,931,020 Ordinary Shares represented by 1,293 Depositary Shares, issuable upon the exercise of Series A Warrants issued in the private placement at an exercise price of $5,360.00 per warrant, (3) 19,396,400 Ordinary Shares represented by 1,939 Depositary Shares, issuable upon the exercise of Series B Warrants issued in the private placement at an exercise price of $5,360.00 per warrant, and (4) 62,184,525 Ordinary Shares represented by 6,218 Depositary Shares, issuable upon the exercise of pre-funded warrants issued in the private placement at an exercise price of $0.80 per warrant, for aggregate gross proceeds of approximately $6.0 million. We also issued unregistered placement agent warrants to purchase a total of 536,800 Ordinary Shares represented by 52 Depositary Shares toLadenburg Thalman & Co. Inc. at an exercise price of $10,000.00 per warrant for one warrants and an exercise price of $5